6 March 2023
Latham & Watkins Advises Revolution Medicines in its US$300.0 Million Public Offering of Common Stock
Capital Markets & IPO Expected to close
Advising firms
Deal team
17 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Mark Roeder Lead | Latham & Watkins LLP | Partner | corporate | Bay Area |
| John Williams Lead | Latham & Watkins LLP | Partner | corporate | Bay Area |
| Zuzanna Gruca | Latham & Watkins LLP | Associate | corporate | Not stated |
| Taimi Jacobson | Latham & Watkins LLP | Associate | corporate | Not stated |
| Suhansi Perera | Latham & Watkins LLP | Associate | corporate | Not stated |
| John Manthei | Latham & Watkins LLP | Partner | regulatory | Washington, D.C. |
| Elizabeth Richards | Latham & Watkins LLP | Partner | regulatory | Washington, D.C. |
| Heather Deixler | Latham & Watkins LLP | Partner | regulatory | Bay Area |
| Betty Pang | Latham & Watkins LLP | Partner | regulatory | Bay Area |
| Nathan Beaton | Latham & Watkins LLP | Associate | regulatory | Washington, D.C. |
| Leia Gu | Latham & Watkins LLP | Associate | regulatory | Los Angeles |
| Jack Chai | Latham & Watkins LLP | Associate | regulatory | Los Angeles |
| Grace Lee | Latham & Watkins LLP | Partner | tax | Bay Area |
| Derek Gumm | Latham & Watkins LLP | Associate | tax | Not stated |
| James Metz | Latham & Watkins LLP | Partner | benefits | Bay Area |
| Christopher Hazuka | Latham & Watkins LLP | Partner | IP | Bay Area |
| Kristina Funahashi | Latham & Watkins LLP | Associate | IP | San Diego |
Stated terms
- Stated value
- USD 300m (US$300.0 million)
- What the figure measures
- Issue size
- Client
- Revolution Medicines, Inc.Issuer
- Counterparties
- Not stated